Previous close | 22.57 |
Open | 21.70 |
Bid | 21.78 x 200 |
Ask | 21.97 x 100 |
Day's range | 21.35 - 22.79 |
52-week range | 5.63 - 26.35 |
Volume | |
Avg. volume | 221,353 |
Market cap | 1.948B |
Beta (5Y monthly) | 0.02 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.15 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 34.71 |
NAARDEN, the Netherlands and MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s
NAARDEN, the Netherlands and MIAMI, May 02, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an R&D Day event for analysts an
Enrollment to continue to the end of April to accommodate strong patient and site interestNAARDEN, the Netherlands and MIAMI, April 09, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently eff